Aeson®: a promising solution for very high-risk patients initially placed on temporary extracorporeal life support Cardiogenic shock is an acute heart failure condition that poses a life ...
The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure ...
10d
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a ...
CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment
Following a strong start this year, we are determined to progressively establish Aeson® as a reference solution for patients suffering from advanced biventricular heart failure — today in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback